Postdoctoral Researcher in Preclinical Radiotheranostics - Nuclear Medicine Department/ATheNO Laboratory – Institut Jules Bordet
As a multicultural university with one third of students and researchers from abroad, international relations is a daily reality for the ULB.
Radiotheranostics is a rapidly emerging cancer therapy that combines patient-specific molecular imaging with targeted delivery of α-or β-emitting radionuclides. This personalised approach, driven by an expanding repertoire of molecular targets and vectors, enables precision oncology across tumour types.
We are seeking a highlymotivated and ambitious postdoctoral researcher to join a preclinical research project focused on radiotheranostics in sarcoma, within the European Thera4Care consortium (https://www.thera4care.eu/). The successful candidate will work at the interface of radiobiology, molecular oncology, and nuclear medicine, using preclinical models to contribute to the development and translation of novel radiotheranostics strategies. This project benefits from a highly collaborative and multidisciplinary research environment, with strong interactions between preclinical researchers and clinicians.
The project will be carried out in Anderlecht (ULB Erasme Campus), in the preclinical and translational laboratory (ATheNO – Advancing Theranostics in Nuclear Oncology) of the Nuclear Medicine department of Institut Jules Bordet.
Key responsibilities
* Design,plan,andexecutepreclinicalstudiesinradiotheranostics(invitroandinvivo)
* Developandoptimizeadvancedcancermodels
* Analyzeandinterpretexperimentaldata,anddisseminatefindingsthroughpublicationsand conferences
* Contributetothedevelopmentandstructuringofagrowingpreclinicallaboratory(ATheNO)
* Superviseandmentorstudentsandtechnicalstaff
* Contributetograntwritingandfundingapplications
* Interactcloselywithclinicalteamsandcollaborators
Candidate profile
We are looking fora proactive and independent scientist eager to work in a multidisciplinary and evolving research environment.
Requiredqualifications:
* PhDinbiomedicalsciencesoranequivalentfield
* Provenexperienceinpreclinicalcancer research
* Strongbackgroundinradiobiologyandradiotheranostics
* Expertiseinadvancedpreclinicalmodels(e.g.patient-derivedmodels)
* Experiencewithimagingtechniques(PET/SPECT/CT)
* Traininginradiationsafetyandhandlingofradioactivematerials
* Solidexpertiseincellular,molecularand(radio)biologicalassays
* Experiencewithmulti-omicsanalysisisconsideredanasset
* Experiencewithinvivomodels(rodentsmodels)-FELASAcertificationisrequired
* Demonstratedabilitytoworkindependentlyandmanageresearchprojects
* Provenscientificwritingskills(publicationsandgrantwriting)
* ExcellentcommunicationskillsandfluencyinEnglish
* Willingnesstotravelforresearchactivities,meetingsandconferences
Personalskills:
* Highlyorganized,proactiveandsolution-oriented
* Strongabilitytoadaptinadevelopingresearchenvironment
* Teamplayerwithleadershippotential
* Interestincontributingtolabstructuringandlong-termdevelopment
About Jules Bordet Institute and the Nuclear Medicine Department
Jules Bordet Institute is a leading comprehensive cancer center in Belgium, fully dedicated to oncology and integrated within the Université Libre de Bruxelles (ULB) medical campus in Anderlecht (Brussels). The Department of Nuclear Medicine has been a pioneer in developing and implementing innovative radiotheranostic therapies, including radioimmunotherapy (RIT) for lymphoma, peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors, and radioligand therapy (RLT) for prostate cancer. Over the past decade, the department has led numerous national “firsts” in radiotheranostics research and clinical translation. Recently, the department established ATheNO (Advancing Theranostics in Nuclear Oncology), a preclinical and translational research laboratory dedicated to advancing radiotheranostics in oncology.
What we offer
* Adynamicandcollaborativeresearchenvironmentwithinarenownedacademichospital
* Auniqueopportunitytocontributetothedevelopmentofanewlaboratory
* Integrationinamultidisciplinaryteamfosteringcloseinteractionbetweenresearchers andclinicians
* Accesstostate-of-the-artpreclinicalresearchinfrastructures
* ParticipationinaninternationalEuropeanconsortium
* Opportunitiesforconferences,networkingandcareerdevelopment
* Initial1-yearcontract(renewable),startingassoonaspossible
* Motivationletterincludingareportonpastresearch
* Contactinformationoftworeferees
#J-18808-Ljbffr